Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Merck
Baxter
Colorcon
Johnson and Johnson

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR TERIFLUNOMIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Teriflunomide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00134563 ↗ Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis Completed Sanofi Phase 3 2004-09-01 The primary objective was to determine the effect of teriflunomide on the frequency of relapses in patients with relapsing multiple sclerosis (MS). Secondary objectives were: - to evaluate the effect of teriflunomide on the accumulation of disability as measured by Expanded Disability Status Scale [EDSS], the burden of disease as measured by Magnetic Resonance Imaging [MRI] and patient-reported fatigue; - to evaluate the safety and tolerability of teriflunomide.
NCT00228163 ↗ Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses Completed Sanofi Phase 2 2002-01-01 The primary objective is to assess the long-term safety of teriflunomide in multiple sclerosis subjects. The secondary objective is to assess the long-term efficacy.
NCT00475865 ↗ Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis Completed Sanofi Phase 2 2007-04-01 The primary objective was to estimate the tolerability and safety of 2 doses of Teriflunomide administered once daily for 24 weeks, compared to placebo, in patients with multiple sclerosis [MS] with relapses who were on a stable dose of Glatiramer Acetate [GA]. The secondary objectives were: - to estimate the effect of the 2 doses of Teriflunomide, compared to placebo, in combination with a stable dose of GA on Magnetic Resonance Imaging [MRI] parameters, relapse rate and patient-reported fatigue; - to perform pharmacokinetic analyses of the 2 doses of teriflunomide in combination with a stable dose of GA.
NCT00489489 ↗ Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis Completed Sanofi Phase 2 2007-05-01 The primary objective was to estimate the tolerability and safety of 2 doses of teriflunomide administered once daily for 24 weeks, compared with placebo, in patients with multiple sclerosis [MS] with relapses who were on a stable dose of interferon-β [IFN-β]. Secondary objectives were: - to estimate the effects of the 2 doses of teriflunomide, compared to placebo, in combination with a stable dose of IFN-β on Magnetic Resonance Imaging [MRI] parameters, relapse rate and patient-reported fatigue; - to perform pharmacokinetic analyses of the 2 doses of teriflunomide in combination with a stable dose of IFN-β.
NCT00622700 ↗ Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis Completed Sanofi Phase 3 2008-02-01 The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day [mg/day] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical episode consistent with multiple sclerosis (MS) to clinically definite multiple sclerosis (CDMS). The secondary objectives were: - To demonstrate the effect of teriflunomide, in comparison to placebo, on: - Reducing conversion to definite multiple sclerosis (DMS) - Reducing annualized relapse rate (ARR) - Reducing disease activity/progression as measured by Magnetic Resonance Imaging (MRI) - Reducing accumulation of disability for at least 12 weeks as measured by the Expanded Disability Status Scale (EDSS) - Proportion of disability-free participants as assessed by the EDSS - Reducing participant-reported fatigue - To evaluate the safety and tolerability of teriflunomide - To evaluate the pharmacokinetics (PK) of teriflunomide - Optional pharmacogenomic testing aimed at assessing the association between the main enzyme systems of teriflunomide metabolism and hepatic safety, and other potential associations between gene variations and clinical outcomes
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Teriflunomide

Condition Name

Condition Name for Teriflunomide
Intervention Trials
Multiple Sclerosis 24
Relapsing Multiple Sclerosis 10
Relapsing Multiple Sclerosis (RMS) 2
Relapsing Remitting Multiple Sclerosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Teriflunomide
Intervention Trials
Multiple Sclerosis 42
Sclerosis 39
Multiple Sclerosis, Relapsing-Remitting 4
Multiple Sclerosis, Chronic Progressive 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Teriflunomide

Trials by Country

Trials by Country for Teriflunomide
Location Trials
United States 317
Canada 39
Spain 36
Italy 34
Germany 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Teriflunomide
Location Trials
Florida 19
Ohio 16
California 15
Michigan 14
Indiana 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Teriflunomide

Clinical Trial Phase

Clinical Trial Phase for Teriflunomide
Clinical Trial Phase Trials
Phase 4 7
Phase 3 25
Phase 2 7
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Teriflunomide
Clinical Trial Phase Trials
Completed 24
Recruiting 13
Active, not recruiting 8
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Teriflunomide

Sponsor Name

Sponsor Name for Teriflunomide
Sponsor Trials
Sanofi 20
Novartis Pharmaceuticals 5
Genzyme, a Sanofi Company 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Teriflunomide
Sponsor Trials
Industry 41
Other 19
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Moodys
Medtronic
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.